Virtual Library
Start Your Search
Inazio Lacambra
Author of
-
+
EP1.04 - Immuno-oncology (ID 194)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.04-07 - Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer (Now Available) (ID 197)
08:00 - 18:00 | Author(s): Inazio Lacambra
- Abstract
Background
Background: The aim of the present study is to analyze the influence of previous radiotherapy (RT) in the efficacy and toxicity in patients (pts) with non small cell lung cáncer (NSCLC) treated with inmunotherapy in second line.
Method
Methods: This is a retrospective study conduted between January 2017 and December 2018 at Hospital Universitario Cruces (Bizkaia) on pts treated with inmunotherapy (nivolumab or pembrolizumab) in second line. The primary end point was to analyze if the RT influence in the progression free survival (PFS) of inmunotherapy or in the toxicity. Secondary end points were overall survival (OS) and if any variable influences the difference between both cohorts in the PFS.
Result
Results: Forty eight pts were evaluated, and 22 (45.83%) had received RT previously. The baseline characteristics were as follows: median age 62 years (range 40-82); 62.5% males; 91.66% had an ECOG performance status (PS) 0-1; 37.5% had stage IV at diagnosis; only 3 of the 22 pts had received less tan 60 grays (Gys). There were no differences in the PFS, 14.49 months (m) in the cohort without RT and 18.19 m in those who have received it (p = 0.196) (image). The incidence of any grade of toxicity was similar, 26.92% and 22.72% in pts without and with RT respectively (p =0.112). 3 pts in the first group stopped inmonotherapy because of toxicity versus 2 pts in the cohort of RT. The OS was significantly longer in the cohort of RT, 36.49 vs. 20.54m, p = 0.034. It was calculated whether the time interval from the end of RT and the initiation of immunotherapy influences on the PFS; neither the cutoff point of 6 months (p = 0.788) nor the cutoff of 4 (p = 0.454) influenced the PFS. As in the second group more patients were diagnosed in EIII, the possible influence of the stage on the PFS was valued, and no significant differences were seen. Neither the previous QT scheme, sex, state of PD-L1 nor the baseline respiratory pathology influenced the PFS or the incidence of toxicity.
Conclusion
Conclusions: Our study suggests that having received prior RT does not influence the efficacy or toxicity of immunotherapy in the second line of treatment in NSCLC. A larger cohort and more follow-up time is needed to be able to draw conclusions.
